Innovent sees path to China approval after eye disease drug matches Eylea in phase 3
Innovent sees path to China approval after eye disease drug matches Eylea in phase 3
Body unavailable. Use the original source.
Innovent sees path to China approval after eye disease drug matches Eylea in phase 3
A compact weekly email covering company moves, product signals, regulatory updates, and notable funding.